Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSD | P07339 | 4/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484061 | 0.87 | PSENEN (0.55) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL14416977 | 0.87 | PSENEN (0.42) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL8835847 | 0.85 | PSENEN (0.71) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL1486221 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL1486223 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL245495 | 0.85 | PSENEN (0.62) | PSENENCTSKCTSSCTSDCA2 | |
| SCHEMBL26818451 | 0.85 | CTSS (0.56) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL22636252 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL22648606 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN | |
| SCHEMBL22636250 | 0.84 | PSENEN (0.63) | PSENENCTSKCTSSCTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015332-A1 | SYNTHESIS METHOD AND APPLICATION OF BENZOTHIASELENAZOLE-1-OXIDE COMPOUND AND DERIVATIVE THEREOF | GUANGZHOU MEDICAL UNIVERSITY (CN) | 2026-01-15 | — | — | US | disclosed |
| CN-117500793-A | Synthesis method and application of benzothiselenazol-1-one compound and derivative thereof | 广州医科大学 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023169082-A1 | SYNTHESIS METHOD AND APPLICATION OF BENZOTHIADIAZOLE-1-KETONE COMPOUND AND DERIVATIVE THEREOF | 广州医科大学 | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015332-A1 | SYNTHESIS METHOD AND APPLICATION OF BENZOTHIASELENAZOLE-1-OXIDE COMPOUND AND DERIVATIVE THEREOF | SARS1, EGFR, ERBB2 | PSENEN 2024/4885CTSK 3053/4885CTSS 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.